During the last session, Rocket Pharmaceuticals Inc (NASDAQ:RCKT)’s traded shares were 4.33 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $3.2, reflecting an intraday gain of 8.11% or $0.24. The 52-week high for the RCKT share is $26.98, that puts it down -743.12 from that peak though still a striking 31.56% gain since the share price plummeted to a 52-week low of $2.19. The company’s market capitalization is $344.76M, and the average intraday trading volume over the past 10 days was 3.78 million shares, and the average trade volume was 5.08 million shares over the past three months.
Rocket Pharmaceuticals Inc (RCKT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. RCKT has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) trade information
Rocket Pharmaceuticals Inc (RCKT) registered a 8.11% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.11% in intraday trading to $3.2, hitting a weekly high. The stock’s 5-day price performance is 23.55%, and it has moved by 4.40% in 30 days. Based on these gigs, the overall price performance for the year is -74.54%. The short interest in Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is 14.04 million shares and it means that shorts have 1.88 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.25, which implies a decrease of -42.22% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2.5 respectively. As a result, RCKT is trading at a premium of 21.88% off the target high and 37.5% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -11.60%. While earnings are projected to return 18.96% in 2025, the next five years will return 21.48% per annum.
RCKT Dividends
Rocket Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT)’s Major holders
Rocket Pharmaceuticals Inc insiders own 2.73% of total outstanding shares while institutional holders control 93.45%, with the float percentage being 96.07%. RTW INVESTMENTS, LP is the largest shareholder of the company, while 325.0 institutions own stock in it. As of 2024-06-30, the company held over 17.69 million shares (or 18.8677% of all shares), a total value of $380.82 million in shares.
The next largest institutional holding, with 9.16 million shares, is of WELLINGTON MANAGEMENT GROUP LLP’s that is approximately 9.7665% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $197.12 million.
Also, the Mutual Funds coming in first place with the largest holdings of Rocket Pharmaceuticals Inc (RCKT) shares are VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Apr 30, 2025 indicates that VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund owns about 4.33 shares. This amounts to just over 4.06 percent of the company’s overall shares, with a $13.87 million market value. The same data shows that the other fund manager holds slightly less at 2.62, or about 2.46% of the stock, which is worth about $8.39 million.
